[1]
|
Ho, D.W., Yang, Z.F., Wong, B.Y., Kwong, D.L., Sham, J.S., Wei, W.I., et al. (2006) Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry serum protein profiling to identify nasopharyngeal carcinoma. Cancer, 107, 99-107. doi:10.1002/cncr.21970
|
[2]
|
Yu, Y., Chen, S., Wang, L.S., Chen, W.L., Guo, W.J., Yan, H., et al. (2005) Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology, 68, 79-86. doi:10.1159/000084824
|
[3]
|
Yang, S.Y., Xiao, X.Y., Zhang, W.G., Zhang, L.J., Zhang, W., Zhou, B., et al. (2005) Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer, 5, 83. doi:10.1186/1471-2407-5-83
|
[4]
|
Liu, W., Guan, M., Wu, D., Zhang, Y., Wu, Z., Xu, M. and Lu, Y. (2005) Using tree analysis pattern and SE- LDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. European Urology, 47, 456-462. doi:10.1016/j.eururo.2004.10.006
|
[5]
|
Srinivasan, R., Daniels, J., Fusaro, V., Lundqvist, A., Killian, J.K., Geho, D., et al. (2006) Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Experimental Hematology, 34, 796-801.
doi:10.1016/j.exphem.2006.02.013
|
[6]
|
Stone, J.H., Rajapakse, V.N., Hoffman, G.S., Specks, U., Merkel, P.A., Spiera, R.F., et al. (2005) A serum proteomic approach to gauging the state of remission in Wegener’s granulomatosis. Arthritis & Rheumatism, 52, 902- 910. doi:10.1002/art.20938
|
[7]
|
Brouwers, F.M., Petricoin 3rd, E.F., Ksinantova, L., Breza, J., Rajapakse, V., Ross, S., et al. (2005) Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. Endocrine-Related Cancer, 12, 263-272. doi:10.1677/erc.1.00913
|
[8]
|
Petricoin, E.F., Rajapaske, V., Herman, E.H., Arekani, A.M., Ross, S., Johann, D., et al. (2004) Toxico-proteomics: Serum proteomic pattern diagnostics for early detection of drug induced cardiac toxicities and cardioprotection. Toxicologic Pathology, 32, 122-130.
doi:10.1080/01926230490426516
|
[9]
|
Ornstein, D.K., Rayford, W., Fusaro, V.A., Conrads, T.P., Ross, S.J., Hitt, B.A., et al. (2004) Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. Journal of Urology, 172, 1302- 1305. doi:10.1097/01.ju.0000139572.88463.39
|
[10]
|
Conrads, T.P., Fusaro, V.A., Ross, S., Johann, D., Rajapakse, V., Hitt, B.A., et al. (2004) High-resolution serum proteomic features for ovarian cancer detection. Endocrine-Related Cancer, 11, 163-178.
doi:10.1677/erc.0.0110163
|
[11]
|
Petricoin, E.F., Fishman, D.A., Conrads, T.P., Veenstra, T.D. and Liotta, L.A. (2003) Proteomic pattern diagnostics: Producers and consumers in the era of correlative science. BMC Bioinformatics, 4, 24.
doi:10.1186/1471-2105-4-24
|
[12]
|
Adam, B.L., Qu, Y., Davis, J.W., Ward, M.D., Clements, M.A., Cazares, L.H., et al. (2002) Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Research, 62, 3609-3614.
|
[13]
|
The BioMarker Discovery Kit.
http://isp.ncifcrf.gov/abcc/abcc-groups/simulation-and-modeling/biomarker-discovery-kit/
|
[14]
|
Habermann, J.K., Roblick, U.J., Luke, B.T., Prieto, D.A., Finlay, W.J., Podust, V.N., et al. (2006) Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology, 131, 1020- 1029. doi:10.1053/j.gastro.2006.07.011
|
[15]
|
Luke, B.T. (2003) Genetic algorithms and beyond. In: Leardi, R., Ed., Nature-Inspired Methods in Chemometrics: Genetic Algorithms and Neural Networks, Chapter 12. Elsevier, Amsterdam.
doi:10.1016/S0922-3487(03)23001-X
|
[16]
|
Ransohoff, D.F. (2005) Lessons from controversy: Ovarian cancer screening and serum proteomics. Journal of the National Cancer Institute, 97, 315-319.
doi:10.1093/jnci/dji054
|
[17]
|
Ransohoff, D.F. (2005) Bias as a threat to the validity of cancer molecular-marker research. Nature Reviews Cancer, 5, 142-149. doi:10.1038/nrc1550
|
[18]
|
Wulfkuhle, J.D., Edmiston, K.H., Liotta, L.A. and Petricoin 3rd, E.F. (2006) Technology insight: Pharmaco-proteomics for cancer—Promises of patient-tailored medicine using protein microarrays. Nature Clinical Practice Oncology, 3, 256-268. doi:10.1038/ncponc0485
|
[19]
|
Gulmann, C., Sheehan, K.M., Kay, E.W., Liotta, L.A., and Petricoin 3rd, E.F. (2006) Array-based proteomics: Mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. Journal of Pathology, 208, 595-606. doi:10.1002/path.1958
|
[20]
|
Petricoin 3rd, E.F., Bichsel, V.E., Calvert, V.S., Espina, V., Winters, M., Young, L., et al. (2005) Mapping molecular networks using proteomics: A vision for patienttailored combination therapy. Journal of Clinical Oncology, 23, 3614-3621. doi:10.1200/JCO.2005.02.509
|
[21]
|
Espina, V., Geho, D., Mehta, A.I., Petricoin 3rd, E.F., Liotta, L.A. and Rosenblatt, K.P. (2005) Pathology of the future: Molecular profiling for targeted therapy. Cancer Investigation, 23, 36-46. doi:10.1081/CNV-46434
|
[22]
|
Calvo, K.R., Liotta, L.A. and Petricoin, E.F. (2005) Clinical proteomics: From biomarker discovery and cell signaling profiles to individualized personal therapy. Bioscience Reports, 25, 107-125.
doi:10.1007/s10540-005-2851-3
|
[23]
|
Anderson, N.L. and Anderson, N.G. (2002) The human plasma proteome: History, character, and diagnostic prospects. Molecular & Cellular Proteomics, 1, 845-867.
doi:10.1074/mcp.R200007-MCP200
|